Cancer metastasis reviews最新文献_第8页

Dissecting the aberrant vasculature of glioblastoma: mechanisms and therapeutic targets. 胶质母细胞瘤异常血管的解剖：机制和治疗靶点。

IF 8.7

Cancer metastasis reviews Pub Date : 2026-03-07 DOI: 10.1007/s10555-026-10319-0

Yinan Li, Yinfei Du, Fan Guan, Xuetong Li, Shu Cui, Wei Gao, Xinmiao Long, Minghua Wu

引用次数: 0

Obesity and melanoma: unraveling the paradoxical survival benefit in immunotherapy. 肥胖和黑色素瘤：解开免疫治疗中矛盾的生存益处。

IF 8.7

Cancer metastasis reviews Pub Date : 2026-03-06 DOI: 10.1007/s10555-026-10324-3

Junjie Yang, Qingqing Hu, Chunyu Xue

{"title":"Obesity and melanoma: unraveling the paradoxical survival benefit in immunotherapy.","authors":"Junjie Yang, Qingqing Hu, Chunyu Xue","doi":"10.1007/s10555-026-10324-3","DOIUrl":"10.1007/s10555-026-10324-3","url":null,"abstract":"The incidence of melanoma has been steadily increasing worldwide, with metastatic disease accounting for a substantial proportion of melanoma-related deaths. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for advanced melanoma, yet patient responses remain highly variable. Interestingly, although obesity is a well-established risk factor for the development of melanoma, paradoxically, emerging clinical data reveal that obese patients may experience superior outcomes following ICI therapy-a phenomenon commonly referred to as the \"obesity paradox\". The biological mechanisms underpinning this paradox remain incompletely elucidated. This review synthesizes current evidence through a critical examination of methodologies used to define obesity in oncology research, followed by an exploration of mechanistic links between obesity and melanomagenesis. We subsequently summarize clinical evidence supporting the obesity paradox in melanoma immunotherapy and discuss potential immune-mediated and metabolic mechanisms underlying this paradoxical association. The review concludes by addressing translational implications of these findings for patient stratification and novel therapeutic strategies.","PeriodicalId":520582,"journal":{"name":"Cancer metastasis reviews","volume":"45 1","pages":""},"PeriodicalIF":8.7,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147370796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient-derived complex organoids are a critical tool to understand and explore pediatric malignant brain tumors. 患者衍生的复杂类器官是了解和探索儿童恶性脑肿瘤的重要工具。

IF 8.7

Cancer metastasis reviews Pub Date : 2026-03-03 DOI: 10.1007/s10555-026-10316-3

Marlène Deschuyter, Sophie Martin, Chinar Salmanli, Clémence Hubsch, Audrey Vincent, Samuel Meignan, Alessandro Furlan, Erika Cosset, Hélène Burckel, Georges Noel, Michel Salzet, Marie Duhamel, Antonella Raffo-Romero, Cedric Boura, Sophie Pinel, Andres Coca, Antony Joud, Mélodie Anne Karnoub, Pascal Chastagner, Sandra Raimbault, Hélène Sudour-Bonnange, Vincent Flacher, Chloé Bernhard, Natacha Entz-Werlé

{"title":"Patient-derived complex organoids are a critical tool to understand and explore pediatric malignant brain tumors.","authors":"Marlène Deschuyter, Sophie Martin, Chinar Salmanli, Clémence Hubsch, Audrey Vincent, Samuel Meignan, Alessandro Furlan, Erika Cosset, Hélène Burckel, Georges Noel, Michel Salzet, Marie Duhamel, Antonella Raffo-Romero, Cedric Boura, Sophie Pinel, Andres Coca, Antony Joud, Mélodie Anne Karnoub, Pascal Chastagner, Sandra Raimbault, Hélène Sudour-Bonnange, Vincent Flacher, Chloé Bernhard, Natacha Entz-Werlé","doi":"10.1007/s10555-026-10316-3","DOIUrl":"10.1007/s10555-026-10316-3","url":null,"abstract":"Pediatric malignant brain tumors (PMBTs) remain among the most common and challenging cancers in children and adolescents, with current therapies often failing to deliver satisfactory outcomes. A major obstacle is their intrinsic and extrinsic resistance mechanisms, underscoring the urgent need for innovative therapeutic strategies and accurate preclinical modeling. Recent advances in organoid-based technologies offer promising tools to mimic PMBTs more faithfully in vitro. These three-dimensional (3D) models can replicate key features of the tumor and its brain-like microenvironment, providing valuable platforms for studying resistant cancer cells and testing novel treatment approaches. This review discusses the relevance of cultured 3D systems, organoids and tumoroids, in pediatric neuro-oncology, emphasizing their role in precision medicine. These models have become essential for dissecting the complex biology and dynamic biological processes of all PMBTs, while bridging clinical challenges with experimental discoveries, ultimately enabling more effective and personalized treatments for young patients.","PeriodicalId":520582,"journal":{"name":"Cancer metastasis reviews","volume":"45 1","pages":""},"PeriodicalIF":8.7,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12957049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147350129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CAR-T cell therapy for pediatric solid tumors: armored CAR-T cells and beyond. CAR-T细胞治疗儿童实体瘤：装甲CAR-T细胞及其他。

IF 8.7

Cancer metastasis reviews Pub Date : 2026-03-02 DOI: 10.1007/s10555-026-10317-2

Jeremy Wells, Ajay Gupta

{"title":"CAR-T cell therapy for pediatric solid tumors: armored CAR-T cells and beyond.","authors":"Jeremy Wells, Ajay Gupta","doi":"10.1007/s10555-026-10317-2","DOIUrl":"10.1007/s10555-026-10317-2","url":null,"abstract":"CAR-T cell therapy, which uses endogenous T cells engineered to target specific cancer antigens, is one of the most promising recent developments in the treatment of hematologic malignancies in both children and adults. CAR-T cells have shown tremendous success in treating B-cell lymphoma, acute lymphoblastic leukemia, and multiple myeloma, and they are currently FDA-approved for the treatment of six hematologic malignancies. Its success in solid tumors has been more modest, which has been attributed to several factors including the hostile tumor microenvironment (TME), poor persistence of CAR-T cells, and difficulty directing CAR-T cells towards solid tumors. Armored CAR-T cells, which modify the TME via secreted cytokines, have shown early success in the treatment of solid pediatric malignancies. We review recent trials of CAR-T cells to treat common pediatric solid malignancies, including Ewing sarcoma, osteosarcoma, neuroblastoma, diffuse intrinsic pontine glioma, rhabdomyosarcoma, Wilms tumor, and retinoblastoma. We focused particularly on armored CAR-T cells where applicable. Armored CAR-T cells have been utilized to target a variety of tumor-associated antigens on pediatric solid tumors with early successes both in vivo and in vitro, and innovative approaches for addressing their limitations are rapidly being developed.","PeriodicalId":520582,"journal":{"name":"Cancer metastasis reviews","volume":"45 1","pages":""},"PeriodicalIF":8.7,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12953346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147329090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Shaping death: how the microbiome regulates tumour cell demise and therapy response. 塑造死亡：微生物组如何调节肿瘤细胞死亡和治疗反应。

IF 8.7

Cancer metastasis reviews Pub Date : 2026-02-20 DOI: 10.1007/s10555-026-10318-1

Martina Raudenska, Jan Balvan, Eliska Zgarbova, David Kalfert, Jan Plzak, Michal Masarik

{"title":"Shaping death: how the microbiome regulates tumour cell demise and therapy response.","authors":"Martina Raudenska, Jan Balvan, Eliska Zgarbova, David Kalfert, Jan Plzak, Michal Masarik","doi":"10.1007/s10555-026-10318-1","DOIUrl":"10.1007/s10555-026-10318-1","url":null,"abstract":"Cell death is a fundamental process that maintains tissue homeostasis and shapes the tumour microenvironment. Cancer cells often evade or reprogram cell death pathways, which leads to malignancy and therapy resistance. On the other hand, the cell death of non-malignant cells significantly influences the adverse effects of anticancer therapy, such as the onset of mucositis or enteritis. Emerging evidence identifies both the tumour and gut microbiomes as critical modulators of these processes. In turn, cell death reshapes the microbial ecosystem by altering nutrient landscapes and immune signalling. Although both cell death and the microbiome are well-studied in cancer, their intersection remains underexplored. This review article addresses this gap by summarising how microbes and microbial metabolites modulate cancer cell death pathways and shape responses to anticancer therapy. We integrated current knowledge on this complex interplay, focusing on key metabolic mediators that can influence cell fate decisions. Understanding this bidirectional crosstalk offers new opportunities to \"preserve the good and eliminate the bad\" within the tumour-microbiome axis, paving the way for precision microbiome-informed cancer therapies.","PeriodicalId":520582,"journal":{"name":"Cancer metastasis reviews","volume":"45 1","pages":"9"},"PeriodicalIF":8.7,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12920367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146230408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Peritoneal carcinomatosis in metastatic Non-Small Cell Lung Cancer: review of the literature. 转移性非小细胞肺癌腹膜癌：文献综述。

IF 8.7

Cancer metastasis reviews Pub Date : 2026-02-19 DOI: 10.1007/s10555-026-10320-7

Fausto Meriggi, Sara Cherri, Diego Gavezzoli, Tony Sabatini, Claudio Bna, Alberto Zaniboni

{"title":"Peritoneal carcinomatosis in metastatic Non-Small Cell Lung Cancer: review of the literature.","authors":"Fausto Meriggi, Sara Cherri, Diego Gavezzoli, Tony Sabatini, Claudio Bna, Alberto Zaniboni","doi":"10.1007/s10555-026-10320-7","DOIUrl":"10.1007/s10555-026-10320-7","url":null,"abstract":"Lung cancer has a remarkably high global incidence and ranks among the most frequent malignancies, with mortality rates placing it first worldwide. Although lung cancer typically metastasizes to the brain, bone, adrenal glands, and liver, the advent and efficacy of novel treatments such as immunotherapy and tyrosine kinase inhibitors have been associated with an increasing incidence of metastases in atypical sites, including peritoneal involvement in Non-Small Cell Lung Cancer. Adenocarcinoma is the histological subtype most frequently responsible for peritoneal carcinomatosis. Little is known about the underlying pathogenic mechanisms leading to peritoneal implantation, and diagnosis is often delayed until advanced disease stages, as symptoms are frequently nonspecific and may be mistaken for the natural progression of advanced lung cancer under systemic oncological treatment. Diagnosis is primarily clinical when ascites develops, but imaging modalities such as computed tomography and fluorodeoxyglucose positron emission tomography/computed tomography can be highly informative. Cytological and molecular analysis of peritoneal fluid obtained via drainage also contributes to diagnosis. Treatment mainly relies on systemic therapy for lung cancer with peritoneal metastases, while loco-regional interventions are generally reserved for symptom control. Considerable progress is still needed in the prevention, early diagnosis, and optimal management of peritoneal carcinomatosis, and future research, despite the rarity of cases, should focus on these aspects. In this review, we aim to analyze the limited literature currently available and explore future directions in the approach to peritoneal carcinomatosis in Non-Small Cell Lung Cancer.","PeriodicalId":520582,"journal":{"name":"Cancer metastasis reviews","volume":"45 1","pages":"8"},"PeriodicalIF":8.7,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12920339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146230449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PD-L1 subpopulations of metastatic urothelial carcinoma demonstrate heterogeneity to chemotherapy: an integrated analysis of digitized trial results. 转移性尿路上皮癌的PD-L1亚群显示化疗的异质性：数字化试验结果的综合分析。

IF 8.7

Cancer metastasis reviews Pub Date : 2026-01-30 DOI: 10.1007/s10555-026-10314-5

Jie Zhou, Xun Jiang, Qing Liu, H Amy Xia, Peng Wei, Brian P Hobbs

{"title":"PD-L1 subpopulations of metastatic urothelial carcinoma demonstrate heterogeneity to chemotherapy: an integrated analysis of digitized trial results.","authors":"Jie Zhou, Xun Jiang, Qing Liu, H Amy Xia, Peng Wei, Brian P Hobbs","doi":"10.1007/s10555-026-10314-5","DOIUrl":"10.1007/s10555-026-10314-5","url":null,"abstract":"Efforts to translate advances in immunology into anti-cancer immunotherapies have progressed rapidly in recent years. Six antibodies acting on programmed death ligand 1 or programmed death 1 pathways were approved in 75 cancer indications between 2015 and 2021. Several of these therapies were granted accelerated approval for specific cancer indications based on evidence from single-arm phase II clinical trials. In the absence of randomization, however, patient prognosis for progression-free and overall survival may not have been studied under standard chemotherapies for PD-1 and PD-L1 biomarker subpopulations. In 2021, two immunotherapies were withdrawn from accelerated approval applications for treatment of metastatic urothelial carcinoma after randomized phase III trials failed to demonstrate evidence for survival advantage over standard of care. This re-analysis uses digitized data to quantify PD-L1 heterogeneity in chemotherapy response, extending prior meta-analyses by incorporating digitized data and design simulation. The findings of the IMvigor210 (NCT02108652) and IMvigor211 (NCT02302807) trials of atezolizumab are reviewed to elucidate the statistical implications of PD-L1 subpopulation heterogeneity. To place the findings into the context of external evidence, digitization software is used to combine results from journal articles of eleven trials that assigned metastatic urothelial carcinoma patients to the same chemotherapy agents administered in the IMvigor211 control arm. This article defines the extent to which PD-L1 IC2/3 subpopulations appeared to outperform historical expectations in the IMvigor211 study based on external evidence from digitized data. Given the extent of PD-L1 heterogeneity suggested by this analysis, trial simulation is applied to define the probability that IMvigor211 would have resulted in a positive trial based on its actual design and alternative designs that enrolled more IC2/3 patients or had longer durations.","PeriodicalId":520582,"journal":{"name":"Cancer metastasis reviews","volume":"45 1","pages":"7"},"PeriodicalIF":8.7,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146088879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of genomic ancestry on tumor genomics in head and neck squamous cell carcinoma. 基因组祖先对头颈部鳞状细胞癌肿瘤基因组学的影响。

IF 8.7

Cancer metastasis reviews Pub Date : 2026-01-30 DOI: 10.1007/s10555-026-10312-7

Madeleine Ndahayo, Anirudh Saxena, Hannah Thomas, Kathryn Hughes Barry, Daria A Gaykalova

引用次数: 0

Aprepitant increases the antitumor activity of chemotherapy by chemosensitizing breast cancer cells. 阿瑞吡坦通过化疗增敏乳腺癌细胞来增加化疗的抗肿瘤活性。

IF 8.7

Cancer metastasis reviews Pub Date : 2026-01-26 DOI: 10.1007/s10555-026-10315-4

Prema Robinson, Marisa Rosso, Yousef Zamil, Miguel Muñoz

引用次数: 0

Engineered bone matrix models for understanding breast cancer skeletal metastasis. 工程骨基质模型用于了解乳腺癌骨骼转移。

IF 8.7

Cancer metastasis reviews Pub Date : 2026-01-24 DOI: 10.1007/s10555-025-10310-1

Kylie M Persson, Matthew A Whitman, Claudia Fischbach

引用次数: 0